Hertfordshire Sept 22: Fluid Pharma Ltd, a licensing and product development company applying its proprietary technologies to advance new therapies for paediatric, geriatric and oral liquid modified release applications, announces a technology partnership with Glatt Pharmaceutical Services to commercialise the MicroCoat™ technology platform within the EU and EAA.
MicroCoat™ is a patent-protected and industrially scalable microparticle coating technology that enables the development of differentiated products for patients with unique needs. Through application of scalable and cost-effective fluid bed coating approaches, MicroCoat™ facilitates the production of functionalised coated microparticles < 200 µm in size, which is the ideal size for manufacture of stable liquid multi-particulate suspension formulations, something that is currently extremely difficult to develop and scale up using conventional coating approaches. Fluid Pharma is now applying this technology to several programs, including applications in taste-masking, patient-centric dosing and gastro-intestinal targeting. As part of the technology partnership, Glatt Pharmaceutical Services will provide customers with cGMP manufacturing and scale up to support clients in all stages of clinical and commercial development.
Dr Fang Liu, Founder of Fluid Pharma Ltd and inventor of the MicroCoat™ technology says “We are extremely pleased to have entered into this technology partnership with Glatt Pharmaceutical Services, an industry recognised specialist manufacturer of multiparticulate systems such as pellets, micropellets and granules. By joining forces, Fluid and Glatt will be able to combine their technology, technical expertise and manufacturing capabilities to bring MicroCoat™ to the market faster. We look forward to applying the MicroCoat™ technology in collaboration with our customers and partners in our effort to develop novel drugs with strong benefits to patients.”,
About Fluid Pharma Ltd: Fluid Pharma is a licensing and product development company applying its proprietary MicroCoat™ technology to advance new therapies for paediatric, geriatric and oral liquid modified release applications. From its laboratories in the UK, Fluid Pharma provides clients access to early dosage form prototyping utilising MicroCoat™ to demonstrate the advantages of the technology for manufacture of stable liquid suspensions and other flexible dosage forms such as orally disintegrating tablets (ODTs) for a wide range of applications, including taste-masking, sustained release and gastro-intestinal targeting.
About Glatt: Glatt Pharmaceutical Services develops and produces solid pharmaceutical dosage forms. Our focus lies on multiparticulate systems such as pellets, micropellets and granules. Whether you are looking for optimal bioavailablity or taste masking, improved solubility or stabilization of the dosage form, we have the right solution for every challenge.
Glatt Pharmaceutical Services brings together fundamentals, experience and innovative technology expertise. With our comprehensive services, we support you from product idea to market launch.
For clinical studies and market supply, we manufacture medicines in bulk and efficiently bring your products to market. Our technical capabilities facilitate a seamless scale-up from the lab to commercial production scale, for which we conduct all requisite analytical studies and stability tests. For optimal processes and a secure investment.
(MicroCoat™ is a trademark of Fluid Pharma Ltd)